Guangxi Wuzhou Zhongheng vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangxi Wuzhou Zhongheng Group Co Ltd (600252.CG)

Q3 202623 Jul – 31 Aug 2026

▲2▼1

Buyback and new drugs offset a first-half loss

Buyback loan backs share cancellation plan ICBC committed up to 180 million yuan for a buyback loan, matching the company's plan to spend 100-200 million yuan repurchasing and cancelling shares. Cancelling shares shrinks the share count, which can lift the value of each remaining share and signals management thinks the stock is cheap.
The loan plus the repurchase-and-cancel plan is the clearest force supporting the share price this period.
Subsidiary adds two products to its pipeline Lummy Pharmaceutical bought global rights to a vitamin D soft capsule for 28 million yuan and won approval to make and sell an inhaled acetylcysteine solution in China. More products broaden future sales sources, though profits from them will take time to show.
These are the only new operating developments that could add future revenue, balancing the weak earnings news.
First-half swing to a 48.8 million yuan loss Revenue fell 29.69% to 725 million yuan and the company swung from a 25.91 million yuan profit to a 48.8 million yuan loss. Industry policy hurt core products, finance costs rose and fund investment income fell. This weak result is the main drag on the stock.
The interim loss is the biggest fundamental negative and directly explains why the stock faces pressure.
Some underlying signs hold up despite the loss Operating cash inflow rose by 110 million yuan to 40.91 million yuan, the debt ratio is a moderate 34.09%, and gross margin improved to 50.90% for a second year. These show the core business still generates cash, softening the loss's impact.
It gives the fair counterweight: not everything in the weak report was bad, which matters for judging the stock.

August 202623 Jul – 31 Aug 2026

▲2▼1

Buyback and new drugs offset a first-half loss

Buyback loan backs share cancellation plan ICBC committed up to 180 million yuan for a buyback loan, matching the company's plan to spend 100-200 million yuan repurchasing and cancelling shares. Cancelling shares shrinks the share count, which can lift the value of each remaining share and signals management thinks the stock is cheap.
The loan plus the repurchase-and-cancel plan is the clearest force supporting the share price this period.
Subsidiary adds two products to its pipeline Lummy Pharmaceutical bought global rights to a vitamin D soft capsule for 28 million yuan and won approval to make and sell an inhaled acetylcysteine solution in China. More products broaden future sales sources, though profits from them will take time to show.
These are the only new operating developments that could add future revenue, balancing the weak earnings news.
First-half swing to a 48.8 million yuan loss Revenue fell 29.69% to 725 million yuan and the company swung from a 25.91 million yuan profit to a 48.8 million yuan loss. Industry policy hurt core products, finance costs rose and fund investment income fell. This weak result is the main drag on the stock.
The interim loss is the biggest fundamental negative and directly explains why the stock faces pressure.
Some underlying signs hold up despite the loss Operating cash inflow rose by 110 million yuan to 40.91 million yuan, the debt ratio is a moderate 34.09%, and gross margin improved to 50.90% for a second year. These show the core business still generates cash, softening the loss's impact.
It gives the fair counterweight: not everything in the weak report was bad, which matters for judging the stock.

Latest23 Jul – 31 Aug 2026

▲2▼1

Buyback and new drugs offset a first-half loss

Buyback loan backs share cancellation plan ICBC committed up to 180 million yuan for a buyback loan, matching the company's plan to spend 100-200 million yuan repurchasing and cancelling shares. Cancelling shares shrinks the share count, which can lift the value of each remaining share and signals management thinks the stock is cheap.
The loan plus the repurchase-and-cancel plan is the clearest force supporting the share price this period.
Subsidiary adds two products to its pipeline Lummy Pharmaceutical bought global rights to a vitamin D soft capsule for 28 million yuan and won approval to make and sell an inhaled acetylcysteine solution in China. More products broaden future sales sources, though profits from them will take time to show.
These are the only new operating developments that could add future revenue, balancing the weak earnings news.
First-half swing to a 48.8 million yuan loss Revenue fell 29.69% to 725 million yuan and the company swung from a 25.91 million yuan profit to a 48.8 million yuan loss. Industry policy hurt core products, finance costs rose and fund investment income fell. This weak result is the main drag on the stock.
The interim loss is the biggest fundamental negative and directly explains why the stock faces pressure.
Some underlying signs hold up despite the loss Operating cash inflow rose by 110 million yuan to 40.91 million yuan, the debt ratio is a moderate 34.09%, and gross margin improved to 50.90% for a second year. These show the core business still generates cash, softening the loss's impact.
It gives the fair counterweight: not everything in the weak report was bad, which matters for judging the stock.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.